HK1100490A1 - Benzothiazepine and benzothiepine compounds - Google Patents

Benzothiazepine and benzothiepine compounds

Info

Publication number
HK1100490A1
HK1100490A1 HK07105658.5A HK07105658A HK1100490A1 HK 1100490 A1 HK1100490 A1 HK 1100490A1 HK 07105658 A HK07105658 A HK 07105658A HK 1100490 A1 HK1100490 A1 HK 1100490A1
Authority
HK
Hong Kong
Prior art keywords
benzothiazepine
therapeutic agent
agent
pharmaceutical useful
preventive agent
Prior art date
Application number
HK07105658.5A
Other languages
English (en)
Inventor
Takehiko Sasahara
Mitsunobu Mohri
Ken-Ichi Kasahara
Original Assignee
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Pharma Corp filed Critical Asahi Kasei Pharma Corp
Publication of HK1100490A1 publication Critical patent/HK1100490A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36—Seven-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK07105658.5A 2004-02-27 2007-05-29 Benzothiazepine and benzothiepine compounds HK1100490A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004128992 2004-02-27
PCT/JP2005/003686 WO2005082874A1 (ja) 2004-02-27 2005-02-25 新規なベンゾチアゼピン及びベンゾチエピン化合物

Publications (1)

Publication Number Publication Date
HK1100490A1 true HK1100490A1 (en) 2007-09-21

Family

ID=34909566

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07105658.5A HK1100490A1 (en) 2004-02-27 2007-05-29 Benzothiazepine and benzothiepine compounds

Country Status (10)

Country Link
US (2) US7973030B2 (xx)
EP (1) EP1719768B1 (xx)
JP (1) JP4711953B2 (xx)
KR (1) KR20070026392A (xx)
CN (2) CN1930137B (xx)
AT (1) ATE555101T1 (xx)
AU (1) AU2005217318B2 (xx)
CA (1) CA2557576C (xx)
HK (1) HK1100490A1 (xx)
WO (1) WO2005082874A1 (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003021569A1 (en) * 2001-08-29 2003-03-13 Tokyo Electron Limited Facility monitor
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US7312208B2 (en) 2002-08-28 2007-12-25 Asahi Kasei Pharma Corporation Quaternary ammonium compounds
WO2009152152A1 (en) * 2008-06-09 2009-12-17 Amarillo Biosciences, Inc. Treatment of obesity with an interferon
CA2744817C (en) 2008-11-26 2020-07-07 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
DK2637668T3 (en) 2010-11-08 2016-08-29 Albireo Ab Ibat inhibitors for the treatment of liver diseases
EP2755480B1 (en) 2011-09-16 2021-03-31 Galectin Therapeutics Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
MX363161B (es) * 2011-10-28 2019-03-13 Lumena Pharmaceuticals Inc Inhibidores de la recirculación de ácidos biliares para el tratamiento de hipercolemia y enfermedad hepática colestásica.
US20140243281A1 (en) * 2011-10-28 2014-08-28 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
BR112014030534A2 (pt) 2012-06-06 2017-06-27 Galectin Therapeutics Inc composições de galacto-ramnogalacturonato para o tratamento de doenças associadas com óxido nítrico sintase induzível elevada
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
JP6751020B2 (ja) 2014-06-25 2020-09-02 Ｅａファーマ株式会社 固形製剤及びその着色防止又は着色低減方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CN106588673B (zh) * 2016-12-20 2018-06-26 金凯(辽宁)化工有限公司 一种2-甲基-5-氨基三氟甲苯的制备方法
WO2018195649A1 (en) * 2017-04-26 2018-11-01 Alberta Research Chemicals Inc. Substituted tetrahydropyridine derivatives as ido-1 inhibitors and uses thereof
WO2019032026A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3100113A1 (en) 2018-06-05 2019-12-12 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
WO2019245448A1 (en) 2018-06-20 2019-12-26 Albireo Ab Crystal modifications of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
JP2023504644A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP2023504643A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CN114761079B (zh) 2019-12-04 2024-05-28 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CA3158276A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023537285A (ja) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
EP4255565A1 (en) 2020-12-04 2023-10-11 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
US20230338392A1 (en) 2022-04-22 2023-10-26 Albireo Ab Subcutaneous administration of an asbt inhibitor
WO2024121434A1 (en) 2022-12-09 2024-06-13 Albireo Ab Asbt inhibitors in the treatment of renal diseases

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203347D0 (en) 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
ZA941003B (en) * 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
IL108634A0 (en) * 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA956647B (en) * 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
US5994391A (en) 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
DE69734100D1 (de) 1996-03-11 2005-10-06 G D Searle Llc St Louis Benzothiepinen mit wirkung als inhibitoren des ileumgallensäuretransports und der taurocholate-aufnahme
IL131872A0 (en) 1997-03-11 2001-03-19 Searle & Co Composition comprising an ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors
DK0864582T3 (da) 1997-03-14 2003-09-29 Aventis Pharma Gmbh Hypolidemiske 1,4-benzothiazepin-1,1-dioxider
BR9814300A (pt) 1997-12-19 2002-02-05 Searle & Co Método de preparação de óxidos de tetraidrobenzotiepina enanciomericamente enriquecidos
ATE240120T1 (de) * 1998-12-23 2003-05-15 Searle Llc Kombinationen von ileumgallensäuretransports inhibitoren und fibronsäure derivaten für kardiovaskuläre indikationen
CN1195748C (zh) * 1999-02-12 2005-04-06 G.D.瑟尔有限公司 具有作为回肠胆汁酸转运和牛磺胆酸摄取抑制剂活性的新的1,2－苯并硫氮杂
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US20020183307A1 (en) 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
EG26979A (en) * 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
WO2002053548A1 (en) 2000-12-27 2002-07-11 Banyu Pharmaceutical Co.,Ltd. Benzothiazepine derivatives
GB0121621D0 (en) * 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
US7312208B2 (en) * 2002-08-28 2007-12-25 Asahi Kasei Pharma Corporation Quaternary ammonium compounds
ATE531701T1 (de) * 2002-08-28 2011-11-15 Asahi Kasei Pharma Corp Neue quaternüre ammoniumverbindungen

Also Published As

Publication number Publication date
CN1930137A (zh) 2007-03-14
JPWO2005082874A1 (ja) 2008-01-17
US20070190041A1 (en) 2007-08-16
US20120015925A1 (en) 2012-01-19
CN102293773A (zh) 2011-12-28
JP4711953B2 (ja) 2011-06-29
AU2005217318A1 (en) 2005-09-09
EP1719768B1 (en) 2012-04-25
CA2557576A1 (en) 2005-09-09
EP1719768A1 (en) 2006-11-08
AU2005217318B2 (en) 2010-07-01
WO2005082874A1 (ja) 2005-09-09
CN1930137B (zh) 2011-07-20
CA2557576C (en) 2010-02-09
ATE555101T1 (de) 2012-05-15
EP1719768A4 (en) 2009-11-04
US7973030B2 (en) 2011-07-05
KR20070026392A (ko) 2007-03-08

Similar Documents

Publication Publication Date Title
HK1100490A1 (en) Benzothiazepine and benzothiepine compounds
ATE531701T1 (de) Neue quaternüre ammoniumverbindungen
EP1830228A4 (en) COMPOSITION FOR A RESERVE AND COMPOSITION SENSITIVE TO RADIATION
DK2168585T3 (da) Farmaceutiske sammensætninger af en neuroaktiv steroid og anvendelser deraf
EP2107909A4 (en) PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF HEPATIC DISORDERS
ZA200800732B (en) Oxidoreductases for the stereoselective reduction of keto compounds
IL178775A0 (en) Pharmaceutical compositions for acute glucocorticoid therapy
IL183973A0 (en) Spm 927 for add -on therapy of schizophrenia
SG119269A1 (en) A material architecture for the fabrication of lowtemperature transistor
AP2005003274A0 (en) Thiazole compounds for the treatment of neurodegenerative disorders
HK1119577A1 (en) Compounds for the treatment of metabolic disorders
PL2004838T3 (pl) Sposób wytwarzania pochodnych steroidowych przez redukcję związków oksosteroidowych albo przez utlenianie związków hydroksysteroidowych, przy użyciu dehydrogenazy hydroksysteroidowej
WO2007087506A3 (en) Compounds for the treatment of metabolic disorders
EP1829540A4 (en) COMPOSITION FOR THE PREVENTION / TREATMENT OF LIVER DISEASES
WO2008021804A3 (en) Therapeutic amides and related compounds
WO2004075840A3 (en) Selective non-steroidal glucocorticoid receptor modulators
IL179337A0 (en) Pharmaceutical compositions for the treatment of pruritus
WO2009082124A3 (en) Pharmaceutical composition for the treatment and prevention of glaucoma
WO2007146856A3 (en) Substituted gamma lactams as therapeutic agents
ZA200609685B (en) Pharmaceutical compositions for acute glucocorticoid therapy
WO2009084835A3 (en) Pharmaceutical composition for treatment and prevention of kidney diseases
EP1707198A4 (en) MEANS TO PREVENT OR PREVENT LIVER DISORDERS WITH HEPATOPATHY
WO2009059047A3 (en) Tricyclic compounds and methods for using the same
ZA200804266B (en) Therapeutic uses of steroidal compounds
FR2897350B1 (fr) Preparation d'un compose comprenant l'association de deux phases cristallines

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)